eicosapentaenoic acid ethyl ester has been researched along with Atherogenesis in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Results from the Colchicine Cardiovascular Outcomes Trial (COLCOT) showed that low-dose colchicine reduces the risk of recurrent CVD events among patients with recent myocardial infarction." | 5.05 | Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. ( Blumenthal, RS; Gulati, M; Mahtta, D; Mehta, A; Sperling, LS; Virani, SS, 2020) |
| "N-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) seem to prevent endothelial dysfunction, a crucial step in atherogenesis, by modulating the levels of vasoactive molecules and by influencing Na,K-ATPase activity of vascular myocytes." | 3.91 | Concentration-Dependent Effects of N-3 Long-Chain Fatty Acids on Na,K-ATPase Activity in Human Endothelial Cells. ( Castiglioni, S; Cazzola, R; Cestaro, B; Della Porta, M; Maier, JAM; Pinotti, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 13 (65.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, MJ | 1 |
| Zamorano, JL | 1 |
| Parhofer, KG | 1 |
| Ridker, PM | 1 |
| Rifai, N | 1 |
| MacFadyen, J | 1 |
| Glynn, RJ | 1 |
| Jiao, L | 1 |
| Steg, PG | 1 |
| Miller, M | 2 |
| Brinton, EA | 1 |
| Jacobson, TA | 1 |
| Tardif, JC | 1 |
| Ballantyne, CM | 5 |
| Mason, RP | 2 |
| Bhatt, DL | 4 |
| Kim, JM | 1 |
| Dagogo-Jack, S | 1 |
| Cherney, DZI | 1 |
| Cosentino, F | 1 |
| McGuire, DK | 1 |
| Pratley, RE | 1 |
| Liu, CC | 1 |
| Cater, NB | 1 |
| Frederich, R | 1 |
| Mancuso, JP | 1 |
| Cannon, CP | 1 |
| Huston, J | 1 |
| Schaffner, H | 1 |
| Cox, A | 1 |
| Sperry, A | 1 |
| Mcgee, S | 1 |
| Lor, P | 1 |
| Langley, L | 1 |
| Skrable, B | 1 |
| Ashchi, M | 1 |
| Bisharat, M | 1 |
| Gore, A | 1 |
| Jones, T | 1 |
| Sutton, D | 1 |
| Sheikh-Ali, M | 1 |
| Berner, J | 1 |
| Goldfaden, R | 1 |
| Bäck, M | 1 |
| Di Costanzo, A | 1 |
| Indolfi, C | 1 |
| Sorrentino, S | 1 |
| Esposito, G | 1 |
| Spaccarotella, CAM | 1 |
| Patel, PN | 1 |
| Patel, SM | 1 |
| Cazzola, R | 1 |
| Della Porta, M | 1 |
| Castiglioni, S | 1 |
| Pinotti, L | 1 |
| Maier, JAM | 1 |
| Cestaro, B | 1 |
| Mehta, A | 1 |
| Mahtta, D | 1 |
| Gulati, M | 1 |
| Sperling, LS | 1 |
| Blumenthal, RS | 1 |
| Virani, SS | 3 |
| Hussain, A | 1 |
| Saeed, A | 1 |
| Ambrosy, AP | 1 |
| Malik, UI | 1 |
| Thomas, RC | 1 |
| Parikh, RV | 1 |
| Tan, TC | 1 |
| Goh, CH | 1 |
| Selby, VN | 1 |
| Solomon, MD | 1 |
| Avula, HR | 1 |
| Fitzpatrick, JK | 1 |
| Skarbinski, J | 1 |
| Philip, S | 3 |
| Granowitz, C | 2 |
| Go, AS | 1 |
| Nelson, JR | 3 |
| Budoff, MJ | 1 |
| Wani, OR | 1 |
| Le, V | 2 |
| Patel, DK | 1 |
| Nelson, A | 1 |
| Nemiroff, RL | 1 |
| Rodriguez-Granillo, GA | 1 |
| Garcia-Garcia, HM | 1 |
| True, WS | 1 |
| Budoff, M | 1 |
| Brent Muhlestein, J | 1 |
| Le, VT | 1 |
| May, HT | 1 |
| Roy, S | 1 |
| Jia, X | 1 |
| Akeroyd, JM | 1 |
| Nasir, K | 1 |
| Nambi, V | 1 |
| Petersen, LA | 1 |
| Orringer, CE | 1 |
| Gitin, A | 1 |
| Hennekens, CH | 1 |
| Bays, HE | 2 |
| Doyle, RT | 2 |
| Juliano, RA | 2 |
| Braeckman, RA | 1 |
| Stirtan, WG | 1 |
| Soni, PN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361] | Phase 3 | 8,179 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy[NCT01047501] | Phase 3 | 702 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL[NCT01047683] | Phase 3 | 229 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 392 |
| Placebo | 507 |
The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 705 |
| Placebo | 901 |
The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 459 |
| Placebo | 606 |
Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 174 |
| Placebo | 213 |
Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 250 |
| Placebo | 355 |
Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 98 |
| Placebo | 134 |
Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 216 |
| Placebo | 321 |
Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 549 |
| Placebo | 690 |
Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 274 |
| Placebo | 310 |
Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 108 |
| Placebo | 157 |
Median percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -2.2 |
| Placebo | 7.1 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -1.8 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.8 |
| Placebo | 6.7 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | 1.5 |
| Placebo | 8.8 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.4 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -5.0 |
| Placebo | 9.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.5 |
| Placebo | 5.9 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047501)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 1.6 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -12.1 |
| Placebo | 15.0 |
Median in percent change from baseline to Week 12 in serum Apolipoprotein B levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 2.1 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -3.8 |
| Placebo | 4.3 |
Median percent change from baseline to Week 12 in serum Lipoprotein-associated Phospholipase A2 levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -5.1 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -17.1 |
| Placebo | -2.4 |
Median percent change from baseline to Week 12 in serum low density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -2.5 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -4.5 |
| Placebo | -3.0 |
Median percent change from baseline to Week 12 in serum non-high density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 0.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -7.7 |
| Placebo | 7.8 |
Median percent change from baseline to Week 12 in fasting serum triglyceride levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | -7.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -26.6 |
| Placebo | 9.7 |
Median percent change from baseline to Week 12 in serum very low-density lipoprotein cholesterol levels following treatment with AMR101 (ethyl icosapentate) 2 g/day or 4 g/day (NCT01047683)
Timeframe: baseline and 12 weeks
| Intervention | Percent change from baseline (Median) |
|---|---|
| AMR101 (Ethyl Icosapentate) - 2 g/Day | 0.0 |
| AMR101 (Ethyl Icosapentate) - 4 g/Day | -19.5 |
| Placebo | 13.7 |
10 reviews available for eicosapentaenoic acid ethyl ester and Atherogenesis
| Article | Year |
|---|---|
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Eicosapentaenoic Acid; Hea | 2022 |
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; | 2023 |
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis.
Topics: Atherosclerosis; Eicosapentaenoic Acid; Humans; Inflammation | 2023 |
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; E | 2023 |
Cardiovascular risk reduction with icosapent ethyl.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Lipid | 2019 |
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.
Topics: American Heart Association; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atheroscler | 2020 |
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Apolipoprotein C-III; Atherosclerosis; Eico | 2020 |
EPA's pleiotropic mechanisms of action: a narrative review.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Eicosapentaenoic Acid; Humans; Lipid Regulating Agents; P | 2021 |
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaqu | 2017 |
Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
Topics: Adult; Aged; Atherosclerosis; Biomarkers; Clinical Decision-Making; Consensus; Dyslipidemias; Eicosa | 2020 |
5 trials available for eicosapentaenoic acid ethyl ester and Atherogenesis
5 other studies available for eicosapentaenoic acid ethyl ester and Atherogenesis
| Article | Year |
|---|---|
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Heart Di | 2023 |
Concentration-Dependent Effects of N-3 Long-Chain Fatty Acids on Na,K-ATPase Activity in Human Endothelial Cells.
Topics: Atherosclerosis; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelial Cells; Homeostasis; Human | 2019 |
Underlying mechanisms involved in the icosapent ethyl reduction of cardiovascular events still cannot be attributed to an anti-atherosclerotic effect.
Topics: Atherosclerosis; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2021 |
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
Topics: Atherosclerosis; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Drug Costs; Dyslipi | 2019 |
Editorial commentary: Icosapent ethyl in the treatment and prevention of cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans | 2020 |